To summarize, the unresolved issue of how to manage the heterogeneity of patients with T2D and to define subgroups with different levels of CV risk is the main barrier to individualized treatment and the reason for the low uptake of GLP-1ra and SGLT2-in drugs, despite accumulating evidence on their CV benefits and decreasing costs. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.